Topic: Placebell©™
The commercial launch of Placebell©™ for peripheral neuropathic pain in October 2017 has increased interest from biopharma industry stakeholders in T4P’s low-risk validated technology.
Following the commercial launch of Placebell©™ in peripheral neuropathic pain in October 2017 and the initiation of the validation of Placebell©™ in osteoarthritis in August 2017,